Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal preparations, medical devices, and laboratory reagents for use in oncology, gynecology, hematology, immunology, and related therapeutic areas in Poland, the rest of the European Union, and internationally. The company operates through the BCG and Traditional segments. The company offers OnkoBCG 50 and 100, which are oncological immunotherapy products used to treat superficial and non-invasive bladder tumors; GAMMA anti-D 50 and GAMMA anti-D 150, which are human anti-rh0(d) immunoglobulin products used in the prevention of maternal-fetal conflict in terms of the D antigen with the Rh system; GAMMA anty HBs 200 medications for use in passive prophylaxis hepatitis B virus; and BCG 10 tuberculosis vaccines. It also provides Distreptaza, a medication for chronic ovarian inflammation and hemorrhoidal disease; LAKCID, which is a lactobacillus probiotic drug; and pseudocholinoesteraza, which is a laboratory reagent. In addition, the company engages in the contract production of injection drugs, lyophilisates of active substances in sterile sealed vials, active substances and drugs based on surface and submerged biological culture, and suppository forms of drugs. The company was formerly known as BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. and changed its name to Synthaverse S.A. in July 2023. Synthaverse S.A. was founded in 1944 and is headquartered in Lublin, Poland.